The loan is made up of six different tranches that can be drawn at Replimune’s option and each matures in October 2027. The loan comes amid the company’s trials directed at cutaneous squamous cell carcinoma and anti-PD1 failed melanoma, according to the Oct. 7 Replimune news release.
“This non-dilutive financing option provides Replimune with significant flexibility as we prepare for key RP1 skin franchise data catalysts and related commercial preparations of our novel tumor-directed oncolytic immunotherapies as well as the advancement of RP2/3 into Phase 2 studies,” Replimune chief financial officer Jean Franchi said. “Not only does this non-dilutive financing strengthen what we believe to be an already strong financial position, it creates optionality in future capital formation and enables us to choose when, and to what extent, we access available funding in order to help manage future cost of capital and dilution.”
